WALTHAM, Mass. — Thermo Fisher Scientific Inc. has completed the sale of its microbiology business to pan-European private equity firm Astorg for approximately $1.075 billion.
The consideration consists of cash and a $50 million seller note, Thermo Fisher said.
The microbiology business provides antimicrobial susceptibility testing and culture media products used in clinical, pharmaceutical and food safety testing.
The unit generated $645 million in revenue in 2025 and was previously part of Thermo Fisher’s Specialty Diagnostics segment.
